Physician profile
Julia Wen
NPI 1831236397
$8,303.10
in general payments reported to CMS, 2019-2025
14 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $984 · 2020: $383 · 2021: $298 · 2022: $2,666 · 2023: $3,507 · 2024: $18.86 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,500 · Food and Beverage: $1,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,500.00 |
| Food and Beverage | $1,471.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $4,156.96 | 2019-2025 | Acuvue, Axert |
| Coopervision INC. | $2,745.07 | 2022-2023 | Misight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $353.51 | 2019-2020 | |
| Glaukos Corporation | $163.51 | 2022 | |
| Allergan, INC. | $143.86 | 2022 | |
| Carl Zeiss Meditec, INC. | $133.09 | 2019 | |
| Shire North American Group INC | $125.00 | 2019 | |
| Dompe US, INC. | $124.98 | 2025 | Oxervate |
| Visioneering Technologies, INC. | $114.21 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $85.34 | 2019 | |
| Oyster Point Pharma, INC. | $76.69 | 2023 | Tyrvaya |
| Alcon Vision LLC | $42.47 | 2023 | Total30 |
| Kala Pharmaceuticals, INC. | $22.37 | 2022 | |
| Sight Sciences, INC. | $16.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Wen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.